IgA Nephropathy and Glomerular Diseases Associated with Infection
By:
Patrick J. Gleeson Hôpital Bichat - Claude-Bernard, Paris, France

Search for other papers by Patrick J. Gleeson in
Current site
Google Scholar
PubMed Close
and
Jonathan Barratt University of Leicester, Leicester, United Kingdom

Search for other papers by Jonathan Barratt in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 24: Issue 1
Published Online:
Mar 2025
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2025 by the American Society of Nephrology 2025
Page Count:
12
Article Category:
Research Article
Print Publication Date:
01 Mar 2025
Published Online:
Mar 2025
  • 1.

    Gleeson PJ, O’Shaughnessy MM, Barratt J: IgA nephropathy in adults-treatment standard. Nephrol Dial Transplant 38: 2464–2473, 2023 10.1093/ndt/gfad146 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Nasr SH, Markowitz GS, Whelan JD, Albanese JJ, Rosen RM, Fein DA, et al.: IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 34: 1235–1241, 2003 10.1016/s0046-8177(03)00424-6 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Nasr SH, D’Agati VD: IgA-dominant postinfectious glomerulonephritis: A new twist on an old disease. Nephron Clin Pract 119: c18–25; discussion c26, 2011 10.1159/000324180 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Nasr SH, Radhakrishnan J, D’Agati VD: Bacterial infection-related glomerulonephritis in adults. Kidney Int 83: 792–803, 2013 10.1038/ki.2012.407 PubMed

  • 5.

    Moriyama T, Karasawa K, Miyabe Y, Akiyama K, Ogura S, Takabe T, et al.: Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors. Sci Rep 10: 11151, 2020 10.1038/s41598-020-68087-y PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, et al.: Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 9: e91756, 2014 10.1371/journal.pone.0091756 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    D’Amico G: Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24: 179–196, 2004 10.1016/j.semnephrol.2004.01.001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Coppo R: Pediatric IgA Nephropathy in Europe. Kidney Dis (Basel) 5: 182–188, 2019 10.1159/000495751 PubMed

  • 9.

    Sevillano AM, Diaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): IgA nephropathy in elderly patients. Clin J Am Soc Nephrol 14: 1183–1192, 2019 10.2215/CJN.13251118 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Glassock RJ: Anticoagulant-related nephropathy: It’s the real McCoy. Clin J Am Soc Nephrol 14: 935–937, 2019 10.2215/CJN.02470319 PubMed

  • 11.

    Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ: The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant 38: 2340–2349, 2023 10.1093/ndt/gfad082 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Kiryluk K, Freedberg DE, Radhakrishnan J, Segall L, Jacobson JS, Mathur M, et al.: Global incidence of IgA nephropathy by race and ethnicity: A systematic review. Kidney360 4: 1112–1122, 2023 10.34067/KID.0000000000000165 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, et al.: Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int 84: 1017–1024, 2013 10.1038/ki.2013.210 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    O’Shaughnessy MM, Hogan SL, Poulton CJ, Falk RJ, Singh HK, Nickeleit V, et al.: Temporal and demographic trends in glomerular disease epidemiology in the southeastern United States, 1986–2015. Clin J Am Soc Nephrol 12: 614–623, 2017 10.2215/CJN.10871016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Caster DJ, Abner CW, Walker PD, Wang K, Heo J, Rava AR, et al.: Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep 8: 1792–1800, 2023 10.1016/j.ekir.2023.06.016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Satoskar AA, Parikh SV, Nadasdy T: Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol 16: 32–50, 2020 10.1038/s41581-019-0178-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Kanjanabuch T, Kittikowit W, Eiam-Ong S: An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 5: 259–269, 2009 10.1038/nrneph.2009.44 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Nasr SH, Fidler ME, Valeri AM, Cornell LD, Sethi S, Zoller A, et al.: Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol 22: 187–195, 2011 10.1681/ASN.2010060611 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al.: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795–1803, 2011 10.1681/ASN.2011050464 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, et al.: Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv 9: eadd6734, 2023 10.1126/sciadv.add6734 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J: Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52: 509–516, 1997 10.1038/ki.1997.361 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Berger J, Yaneva H, Nabarra B, Barbanel C: Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int 7: 232–241, 1975 10.1038/ki.1975.35 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Cambier A, Gleeson PJ, Abbad L, Canesi F, da Silva J, Bex-Coudrat J, et al.: Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy. Kidney Int 101: 274–287, 2022 10.1016/j.kint.2021.09.023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Silva FG, Chander P, Pirani CL, Hardy MA: Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33: 241–246, 1982 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Chou Y-L, Chen H-L, Hsu B-G, Yang C-Y, Chen C-H, Lee Y-C, et al.: Galectin-3 contributes to pathogenesis of IgA nephropathy. Kidney Int 106: 658–670, 2024 10.1016/j.kint.2024.06.023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, et al.: TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97: 340–349, 2020 10.1016/j.kint.2019.08.022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Zhu Y, He H, Sun W, Wu J, Xiao Y, Peng Y, et al.: IgA nephropathy: Gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway. Nephrol Dial Transplant 39: 1624–1641, 2024 10.1093/ndt/gfae052 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Levy M: Cas familiaux de maladie de Berger ou de maladie de Berger et de purpura rhumatoide. Etude cooperative de la Societe Francaise de Nephrologie [Familial cases of Berger’s disease or of Berger’s disease and rheumatoid purpura. Cooperative study of the Societe Francaise de Nephrologie]. Nephrologie 10: 175–182, 1989 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ: Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 312: 202–208, 1985 10.1056/NEJM198501243120403 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Karnib HH, Sanna-Cherchi S, Zalloua PA, Medawar W, D’Agati VD, Lifton RP, et al.: Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant 22: 772–777, 2007 10.1093/ndt/gfl677 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    O’Connell PJ, Ibels LS, Thomas MA, Harris M, Eckstein RP: Familial IgA nephropathy: A study of renal disease in an Australian aboriginal family. Aust N Z J Med 17: 27–33, 1987 10.1111/j.1445-5994.1987.tb05045.x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Magistroni R, D’Agati VD, Appel GB, Kiryluk K: New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88: 974–989, 2015 10.1038/ki.2015.252 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, et al.: Familial clustering of IgA nephropathy: Further evidence in an Italian population. Am J Kidney Dis 33: 857–865, 1999 10.1016/s0272-6386(99)70417-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Tsuboi N, Kawamura T, Okonogi H, Ishii T, Utsunomiya Y, Hosoya T: Discordant clinicopathological features in monozygotic twins with IgA nephropathy. Nephrol Dial Transplant 26: 4146–4148, 2011 10.1093/ndt/gfr519 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Masuda J, Shiiki H, Fujii Y, Dohi K, Harada A: [Identical twin sisters with IgA nephropathy]. Nihon Jinzo Gakkai Shi 38: 52–56, 1996 PubMed

  • 36.

    Irvine J, Cross N, Lynn K, Robson R, Searle M, Morton J, et al.: IgA nephropathy in identical twins: An excellent donor and recipient outcome 11 years after transplantation. Clin Kidney J 5: 232–233, 2012 10.1093/ckj/sfs022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Ahlmen J, Hedman I, Svalander C: Recurrent IgA-nephropathy in an identical twin transplant. Clin Transpl 1989: 297, 1989 PubMed

  • 38.

    Wei M, Meng S, Shi S, Liu L, Zhou X, Lv J, et al.: Monozygotic twins discordant for immunoglobulin A nephropathy display differences in DNA methylation and gene expression. Kidney Dis (Basel) 7: 200–209, 2021 10.1159/000512169 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, et al.: HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 21: 1791–1797, 2010 10.1681/ASN.2010010076 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al.: Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321–327, 2011 10.1038/ng.787 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Yu X-Q, Li M, Zhang H, Low H-Q, Wei X, Wang J-Q, et al.: A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44: 178–182, 2011 10.1038/ng.1047 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al.: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187–1196, 2014 10.1038/ng.3118 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Li M, Foo J-N, Wang J-Q, Low H-Q, Tang X-Q, Toh K-Y, et al.: Identification of new susceptibility loci for IgA nephropathy in Han Chinese. Nat Commun 6: 7270, 2015 10.1038/ncomms8270 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Li M, Wang L, Shi D-C, Foo J-N, Zhong Z, Khor C-C, et al.: Genome-wide meta-analysis identifies three novel susceptibility loci and reveals ethnic heterogeneity of genetic susceptibility for IgA nephropathy. J Am Soc Nephrol 31: 2949–2963, 2020 10.1681/ASN.2019080799 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Kiryluk K, Sanchez-Rodriguez E, Zhou X-J, Zanoni F, Liu L, Mladkova N, et al.: Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 55: 1091–1105, 2023 10.1038/s41588-023-01422-x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Li M, Wang Y-N, Wang L, Meah W-Y, Shi D-C, Heng K-K, et al.: Genome-wide association analysis of protein-coding variants in IgA nephropathy. J Am Soc Nephrol 34: 1900–1913, 2023 10.1681/ASN.0000000000000222 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Gleeson PJ, Benech N, Chemouny J, Metallinou E, Berthelot L, da Silva J, et al.: The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis. Sci Transl Med 16: eadl6149, 2024 10.1126/scitranslmed.adl6149 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Liang X, Zhang S, Zhang D, Hu L, Zhang L, Peng Y, et al.: Metagenomics-based systematic analysis reveals that gut microbiota Gd-IgA1-associated enzymes may play a key role in IgA nephropathy. Front Mol Biosci 9: 970723, 2022 10.3389/fmolb.2022.970723 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al.: Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 76: 1614–1622, 2017 10.1136/annrheumdis-2016-211064 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Dong R, Bai M, Zhao J, Wang D, Ning X, Sun S: A comparative study of the gut microbiota associated with immunoglobulin a nephropathy and membranous nephropathy. Front Cell Infect Microbiol 10: 557368, 2020 10.3389/fcimb.2020.557368 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L, et al.: Alterations of the human gut microbiome in chronic kidney disease. Adv Sci (Weinh) 7: 2001936, 2020 10.1002/advs.202001936 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Zhao J, Bai M, Ning X, Qin Y, Wang Y, Yu Z, et al.: Expansion of Escherichia-Shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy. J Am Soc Nephrol 33: 2276–2292, 2022 10.1681/ASN.2022020189 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Zhao J, Bai M, Yang X, Wang Y, Li R, Sun S: Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: The first case reports. Ren Fail 43: 928–933, 2021 10.1080/0886022X.2021.1936038 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Zhang M, Zhou W, Liu S, Zhang L, Ni Z, Hao C: KM55 monoclonal antibody staining in IgA-dominant infection-related glomerulonephritis. Nephron 145: 225–237, 2021 10.1159/000513269 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Hirayama K, Kobayashi M, Kondoh M, Muro K, Iwabuchi S, Yoh K, et al.: Henoch-Schonlein purpura nephritis associated with methicillin-resistant Staphylococcus aureus infection. Nephrol Dial Transplant 13: 2703–2704, 1998 10.1093/ndt/13.10.2703 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Chauvet S, Berthaud R, Devriese M, Mignotet M, Vieira Martins P, Robe-Rybkine T, et al.: Anti-factor B antibodies and acute postinfectious GN in children. J Am Soc Nephrol 31: 829–840, 2020 10.1681/ASN.2019080851 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, et al.; SONG-GD Investigators: Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clin J Am Soc Nephrol 15: 673–684, 2020 10.2215/CJN.13101019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Kerklaan J, Hannan E, Hanson C, Guha C, Cho Y, Christian M, et al.: Perspectives on life participation by young adults with chronic kidney disease: An interview study. BMJ Open 10: e037840, 2020 10.1136/bmjopen-2020-037840 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Jhaveri KD, Bensink ME, Bunke M, Briggs JA, Cork DMW, Jeyabalan A: Humanistic and economic burden of IgA nephropathy: Systematic literature reviews and narrative synthesis. Pharmacoecon Open 7: 709–722, 2023 10.1007/s41669-023-00415-0 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Szklarzewicz J, Floege U, Gallego D, Gibson K, Kalantar-Zadeh K, Helm K, et al.: The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States. Qual Life Res, 2024 10.1007/s11136-024-03813-x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Yang N, Tang J, Li X, Li D, Zhu B, He Q, et al.: A patient report scale research to access the symptom burden in patients with IgA nephropathy. Sci Rep 14: 22104, 2024 10.1038/s41598-024-59586-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts ISD, Feehally J, et al.; Oxford Derivation North American Validation and VALIGA Consortia: The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89: 167–175, 2016 10.1038/ki.2015.322 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al.: Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18: 727–738, 2023 10.2215/CJN.0000000000000135 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Jarrick S, Lundberg S, Welander A, Carrero J-J, Höijer J, Bottai M, et al.: Mortality in IgA nephropathy: A nationwide population-based cohort study. J Am Soc Nephrol 30: 866–876, 2019 10.1681/ASN.2018101017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Lee H, Kim DK, Oh K-H, Joo KW, Kim YS, Chae D-W, et al.: Mortality of IgA nephropathy patients: A single center experience over 30 years. PLoS One 7: e51225, 2012 10.1371/journal.pone.0051225 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Glassock RJ: Mortality Risk in IgA Nephropathy. J Am Soc Nephrol 30: 720–722, 2019 10.1681/ASN.2018121255 PubMed

  • 67.

    Sevillano AM, Caravaca-Fontán F, Cordero Garcia-Galan L, Fernandez-Juarez G, Lopez-Revuelta K, Guzmán DA, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effect of immunosuppressive treatments on kidney outcomes after gross hematuria-related acute kidney injury in older patients with IgA nephropathy. Kidney Int Rep 8: 1596–1604, 2023 10.1016/j.ekir.2023.05.027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Huang Z, Chen B, Zhou Y, Liang Y, Qiu W, Lv Y, et al.: Clinicopathological and prognostic study of IgA-dominant postinfectious glomerulonephritis. BMC Nephrol 22: 248, 2021 10.1186/s12882-021-02462-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Barbour SJ, Coppo R, Zhang H, Liu Z-H, Suzuki Y, Matsuzaki K, et al.; International IgA Nephropathy Network: Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med 179: 942–952, 2019 10.1001/jamainternmed.2019.0600 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1–S276, 2021 10.1016/j.kint.2021.05.021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Barbour SJ, Coppo R, Er L, Russo ML, Liu Z-H, Ding J, et al.; International IgA Nephropathy Network Research Group: Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy. Kidney Int 106: 913–927, 2024 10.1016/j.kint.2024.07.012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Barbour SJ, Coppo R, Er L, Russo ML, Liu Z-H, Ding J, et al.; International IgA Nephropathy Network: Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int 99: 1439–1450, 2021 10.1016/j.kint.2020.10.033 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Bellur SS, Troyanov S, Vorobyeva O, Coppo R, Roberts ISD, Validation in IgAN Study Group: Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 105: 1279–1290, 2024 10.1016/j.kint.2024.03.011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, et al.: Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. PLoS One 13: e0206865, 2018 10.1371/journal.pone.0206865 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Maixnerova D, Ling C, Hall S, Reily C, Brown R, Neprasova M, et al.: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PLoS One 14: e0212254, 2019 10.1371/journal.pone.0212254 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Martín-Penagos L, Fernández-Fresnedo G, Benito-Hernández A, Mazón J, de Cos M, Oviedo MV, et al.: Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression. Nefrologia (Engl Ed) 41: 311–320, 2021 10.1016/j.nefroe.2021.06.004 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al.: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579–1587, 2012 10.1681/ASN.2012010053 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Maeda A, Gohda T, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal 17: 73–76, 2003 10.1002/jcla.10071 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Gong W-Y, Liu M, Luo D, Liu F-N, Yin L-H, Li Y-Q, et al.: High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria </= 1 g/d: An observational cross-sectional study. BMC Nephrol 20: 150, 2019 10.1186/s12882-019-1331-0 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Liu L, Zhang Y, Duan X, Peng Q, Liu Q, Zhou Y, et al.: C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J Clin Immunol 34: 224–232, 2014 10.1007/s10875-013-9970-6 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Torres DD, Rossini M, Manno C, Mattace-Raso F, D’Altri C, Ranieri E, et al.: The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73: 327–333, 2008 10.1038/sj.ki.5002621 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Hisano S, Joh K, Katafuchi R, Shimizu A, Hashiguchi N, Kawamura T, et al.; Ministry of Health, Labor and Welfare of Japan: Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: The authors reply. Clin Exp Nephrol 21: 1137–1138, 2017 10.1007/s10157-017-1422-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Gong S, Jin S, Li Y, Jiang W, Zhang Z, Shen Z, et al.: Urinary soluble CD163 levels predict IgA nephropathy remission status. Front Immunol 12: 769802, 2021 10.3389/fimmu.2021.769802 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Li J, Lv J, Wong MG, Shi S, Zan J, Monaghan H, TESTING Study Biomarker Group, et al.: Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy. Kidney Int Rep 9: 3016–3026, 2024 10.1016/j.ekir.2024.07.031 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Ștefan G, Jullien P, Masson I, Alamartine E, Mariat C, Maillard N: Circulating alternative pathway complement cleavage factor Bb is associated with vascular lesions and outcomes in IgA nephropathy. Nephrol Dial Transplant 38: ii11–ii18, 2023 10.1093/ndt/gfad163 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Medjeral-Thomas NR, Cook HT, Pickering MC: Complement activation in IgA nephropathy. Semin Immunopathol 43: 679–690, 2021 10.1007/s00281-021-00882-9 PubMed

  • 87.

    Paueksakon P, Najafian B, Alpers CE, Fogo AB: AJKD atlas of renal pathology: IgA-dominant infection-related glomerulonephritis. Am J Kidney Dis 83: e1–e2, 2024 10.1053/j.ajkd.2023.05.009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Xie D, Zhao H, Xu X, Zhou Z, Su C, Jia N, et al.: Intensity of macrophage infiltration in glomeruli predicts response to immunosuppressive therapy in patients with IgA nephropathy. J Am Soc Nephrol 32: 3187–3196, 2021 10.1681/ASN.2021060815 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Yoshimura M, Kida H, Abe T, Takeda S, Katagiri M, Hattori N: Significance of IgA deposits on the glomerular capillary walls in IgA nephropathy. Am J Kidney Dis 9: 404–409, 1987 10.1016/s0272-6386(87)80143-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Fogo AB, Lusco MA, Najafian B, Alpers CE: AJKD atlas of renal pathology: IgA nephropathy. Am J Kidney Dis 66: e33-4–e34, 2015 10.1053/j.ajkd.2015.08.001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Brodsky SV, Nadasdy T, Cassol C, Satoskar A: IgA staining patterns differentiate between IgA nephropathy and IgA-dominant infection-associated glomerulonephritis. Kidney Int Rep 5: 909–911, 2020 10.1016/j.ekir.2020.03.029 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177–3183, 2007 10.1681/ASN.2007050526 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578–1583, 2003 10.1097/01.asn.0000068460.37369.dc PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Li PK-T, Leung CB, Chow KM, Cheng YL, Fung SK-S, Mak SK, et al.; HKVIN Study Group: Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751–760, 2006 10.1053/j.ajkd.2006.01.017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, et al.: Early change in urine protein as a surrogate end point in studies of IgA nephropathy: An individual-patient meta-analysis. Am J Kidney Dis 68: 392–401, 2016 10.1053/j.ajkd.2016.02.042 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al.; DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020 10.1056/NEJMoa2024816 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al.; The EMPA-KIDNEY Collaborative Group: Empagliflozin in patients with chronic kidney disease. N Engl J Med 388: 117–127, 2023 10.1056/NEJMoa2204233 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, et al. DAPA-CKD Trial Committees and Investigators: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100: 215–224, 2021 10.1016/j.kint.2021.03.033 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Nuffield Department of Population Health Renal Studies Group; SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet 400: 1788–1801, 2022 10.1016/S0140-6736(22)02074-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Kohan DE, Barratt J, Heerspink HJL, Campbell KN, Camargo M, Ogbaa I, et al.: Targeting the endothelin A receptor in IgA nephropathy. Kidney Int Rep 8: 2198–2210, 2023 10.1016/j.ekir.2023.07.023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, et al.; DUPRO steering committee and PROTECT Investigators: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402: 2077–2090, 2023 10.1016/S0140-6736(23)02302-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, et al.; ALIGN Study Investigators: Atrasentan in patients with IgA nephropathy. N Engl J Med 392: 544–554, 2024 10.1056/NEJMoa2409415 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al.; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017 10.1001/jama.2017.9362 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al.; TESTING Study Group: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327: 1888–1898, 2022 10.1001/jama.2022.5368 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Kim D, Lv J, Hladunewich M, Jha V, Hooi LS, Monaghan H, et al.; TESTING trial steering committee: The efficacy and safety of reduced-dose oral methylprednisolone in high-risk immunoglobulin A nephropathy. Kidney Int Rep 9: 2168–2179, 2024 10.1016/j.ekir.2024.03.032 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Tang S, Leung JCK, Chan LYY, Lui YH, Tang CSO, Kan CH, et al.: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68: 802–812, 2005 10.1111/j.1523-1755.2005.00460.x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN: Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77: 543–549, 2010 10.1038/ki.2009.499 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, et al.; MAIN Trial Investigators: Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: A randomized clinical trial. JAMA Netw Open 6: e2254054, 2023 10.1001/jamanetworkopen.2022.54054 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Hou J-H, Le W-B, Chen N, Wang W-M, Liu Z-S, Liu D, et al.: Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: A randomized controlled trial. Am J Kidney Dis 69: 788–795, 2017 10.1053/j.ajkd.2016.11.027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Stefan G, Mircescu G: Hydroxychloroquine in IgA nephropathy: A systematic review. Ren Fail 43: 1520–1527, 2021 10.1080/0886022X.2021.2000875 PubMed

  • 111.

    Liu L-J, Yang Y-Z, Shi S-F, Bao Y-F, Yang C, Zhu S-N, et al.: Effects of hydroxychloroquine on proteinuria in IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 74: 15–22, 2019 10.1053/j.ajkd.2019.01.026 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al.; NefIgArd Trial Investigators: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103: 391–402, 2022 10.1016/j.kint.2022.09.017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, et al.; NefIgArd trial investigators: Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402: 859–870, 2023 10.1016/S0140-6736(23)01554-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu M-S, et al.; SANCTUARY Study Investigators: Efficacy and safety of ravulizumab in IgA nephropathy: A phase 2 randomized double-blind placebo-controlled trial [published online ahead of print Oct 25, 2024]. J Am Soc Nephrol, doi:10.1681/ASN.0000000534 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Barratt J, Barbour SJ, Brenner RM, Cooper K, Wei X, Eren N, et al.; ORIGIN Phase 2b Investigators: Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy. J Am Soc Nephrol, 2024 10.1681/ASN.0000000541 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh K-H, et al.; ENVISION Trial Investigators Group: A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med 390: 20–31, 2024 10.1056/NEJMoa2305635 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, et al.: Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 105: 189–199, 2024 10.1016/j.kint.2023.09.027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al.; APPLAUSE-IgAN Investigators: Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med 392: 531–543, 2024 10.1056/NEJMoa2410316 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, et al.; Cemdisiran Phase 2 Study Investigators and Collaborators: Phase 2 trial of cemdisirancin adult patients with IgA nephropathy: A randomized controlled trial. Clin J Am Soc Nephrol 19: 452–462, 2024 10.2215/CJN.0000000000000384 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, et al.: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood 133: 530–539, 2019 10.1182/blood-2018-09-876136 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, et al.: A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int 105: 1306–1315, 2024 10.1016/j.kint.2024.03.012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Arivazhagan S, Lamech TM, Myvizhiselvi M, Arumugam V, Alavudeen SS, Dakshinamoorthy S, et al.: Efficacy of corticosteroids in infection-related glomerulonephritis–A randomized controlled trial. Kidney Int Rep 7: 2160–2165, 2022 10.1016/j.ekir.2022.07.163 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1157 1157 1117
Full Text Views 169 169 111
PDF Downloads 261 261 162